{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:07:18Z","timestamp":1790298438871,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004678","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,5,12]],"date-time":"2010-05-12T00:00:00Z","timestamp":1273622400000}}],"reference-count":161,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004678.pub2","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T16:33:02Z","timestamp":1273595582000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Glatiramer acetate for multiple sclerosis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Loredana","family":"La Mantia","sequence":"first","affiliation":[{"name":"Fondazione I.R.C.C.S. - Istituto Neurologico C. Besta; Department of Neuroscience; Via Celoria, 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca M","family":"Munari","sequence":"additional","affiliation":[{"name":"Sapio Life; Via Silvio Pellico 48 Monza Italy 20052"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lovati","sequence":"additional","affiliation":[{"name":"Ospedale San Paolo; U.O. Oncologia; Di Rudini, 8 Milano Italy 20142"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,12]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD004678.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis","volume":"317","author":"Bornstein","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/WNL.41.4.533","article-title":"A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis","volume":"41","author":"Bornstein","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0003|cit3","first-page":"A289","article-title":"The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment","volume":"52 Suppl 2","author":"Comi","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0004|cit4","first-page":"187","article-title":"The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"Suppl 1","author":"Comi","year":"2001","journal-title":"Journal of Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis","volume":"149","author":"Comi","year":"2001","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.57.4.731","article-title":"Glatiramer acetate reduces the proportion of new MS lesions evolving into \"black holes\"","volume":"57","author":"Filippi","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1352458506070704","article-title":"Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European\/Canadian double-blind, placebo-controlled, MRI-monitored trial","volume":"13","author":"Rovaris","year":"2007","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0008|cit8","first-page":"187","article-title":"The effect of glatiramer acetate on brain volume changes in patients with relapsing-remitting multiple sclerosis","volume":"94 Suppl 1","author":"Rovaris","year":"2001","journal-title":"Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(06)70327-1","article-title":"Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study","volume":"5","author":"Filippi","year":"2006","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0010|cit10","unstructured":"Markowitz C A multinational, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of 2 doses of glatiramer acetate orally administered in relapsing remitting multiple sclerosis patients http:\/\/www.uphs.upenn.edu\/neuro\/clintrial\/MS-Coral-Markowitz.htm"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00415-008-0924-5","article-title":"Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study","volume":"255","author":"Mesaros","year":"2008","journal-title":"Journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.neurol.2008.02.045","article-title":"Long-term effects of glatiramer acetate in multiple sclerosis","volume":"164","author":"Brochet","year":"2008","journal-title":"Revue Neurologique"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.54.4.813","article-title":"Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment","volume":"54","author":"Ge","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.52.4.894-c","article-title":"Extended use of glatiramer acetate (Copaxone) for MS [Letter]","volume":"52","author":"Greenstein","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0020|cit15","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/ana.410360727","article-title":"Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1","volume":"36 Suppl","author":"Johnson","year":"1994","journal-title":"Annals Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004678.pub2-BIB0021|cit16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135245859600100606","article-title":"Management of relapsing\/remitting multiple sclerosis with copolymer 1 (Copaxone)","volume":"1","author":"Johnson","year":"1996","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0022|cit17","first-page":"973","article-title":"The U.S.Phase III Copolymer 1 Study Group. Antibodies to Copolymer 1 do not interfere with the clinical effect [Abstract]","volume":"38","author":"Johnson","year":"1995","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004678.pub2-BIB0015|cit18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double.-blind, placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0016|cit19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.50.3.701","article-title":"Extended use of glatiramer acetate (copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group","volume":"50","author":"Johnson","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0017|cit20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group","volume":"6","author":"Johnson","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0018|cit21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1191\/1352458503ms961oa","article-title":"Glatiramer acetate (Copaxone) : comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial","volume":"9","author":"Johnson","year":"2003","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0019|cit22","first-page":"S38","article-title":"Effects of copolymer on neurologic disability in patients with relapsing-remitting multiple sclerosis: results of a phase III trial [Abstract]","volume":"242","author":"Johnson","year":"1995","journal-title":"Journal of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-510X(00)00401-9","article-title":"Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability\/time curves. The Copolymer 1 Multiple Sclerosis Study Group","volume":"181","author":"Liu","year":"2000","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0024|cit24","first-page":"103","article-title":"Copolymer-1 reduces the relapse rate and positively influences disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center double-blind, placebo- controlled trial [Abstract]","volume":"2","author":"Schiffer","year":"1995","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2007.01.070","article-title":"Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial","volume":"255","author":"Schwid","year":"2007","journal-title":"Journal of the neurological sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0026|cit26","unstructured":"Markowitz C A multinational, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in primary progressive multiple sclerosis patients http:\/\/www.uphs.upenn.edu\/neuro\/clintrial\/MS-Promise-Markowitz.htm 2000"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/1352458507079907","article-title":"longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate : multicenter study","volume":"14","author":"Sajja","year":"2008","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0029|cit28","first-page":"S65","article-title":"The PROMiSe trial: baseline data review and progress report","volume":"10 Suppl 1","author":"Wolinsky","year":"2004","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0028|cit29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Annals of neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0022-510X(77)90220-9","article-title":"Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report","volume":"31","author":"Abramsky","year":"1977","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast cancer research and treatment"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-008-0911-x","article-title":"Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in Multiple Sclerosis","volume":"255","author":"Arnold","year":"2008","journal-title":"Journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1600-0560.2007.00819.x","article-title":"Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases","volume":"35","author":"Ball","year":"2008","journal-title":"Journal of cutaneous pathology"},{"issue":"7","key":"10.1002\/14651858.CD004678.pub2-BIB0034|cit34","first-page":"69","article-title":"Copolymer 1 as therapy for multiple sclerosis: the cons","volume":"38 Suppl 2","author":"Baumhefner","year":"1988","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0035|cit35","first-page":"270","article-title":"Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study","volume":"406","author":"Blanco","year":"2006","journal-title":"Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0036|cit36","first-page":"101","article-title":"[The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy]","volume":"Spec No 3","author":"Boiko","year":"2006","journal-title":"Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova \/ Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov."},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.410110314","article-title":"Multiple sclerosis: trial of a synthetic polypeptide","volume":"11","author":"Bornstein","year":"1982","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-006-0233-9","article-title":"Necrotising cutaneous lesions as a side effect of glatiramer acetate","volume":"253","author":"Bosca","year":"2006","journal-title":"Journal of neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-5728(01)00250-8","article-title":"Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone","volume":"115","author":"Brenner","year":"2001","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.neurol.2008.02.045","article-title":"Long-term effects of glatiramer acetate in multiple sclerosis","volume":"164","author":"Brochet","year":"2008","journal-title":"Revue Neurologique"},{"issue":"23","key":"10.1002\/14651858.CD004678.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-1331.2006.01273.x","article-title":"Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis","volume":"13","author":"Caon","year":"2006","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s10072-008-0945-y","article-title":"Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients","volume":"29","author":"Capobianco","year":"2008","journal-title":"Neurological sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1468-1331.2008.02071.x","article-title":"Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"15","author":"Carra","year":"2008","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-008-0077-z","article-title":"Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patient","volume":"25","author":"Castelli-Haley","year":"2008","journal-title":"Advances in therapy"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000143156","article-title":"Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone","volume":"77","author":"Charach","year":"2008","journal-title":"Digestion"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/135245850100700401","article-title":"Glatiramer acetate induces a Th2-biased response and cross reactivity with myelin basic protein in patients with MS","volume":"7","author":"Chen","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/09546630801961067","article-title":"An urticarial vasculitis case induced by glatiramer acetate","volume":"19","author":"Cicek","year":"2008","journal-title":"The Journal of dermatological treatment"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0049|cit49","first-page":"A470","article-title":"Assessment of the efficacy of Copolymer-1 in the Treatment of Multiple Sclerosis by Quantitative MRI","volume":"45 Suppl 4","author":"Cohen","year":"1995","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/01.wnl.0000257109.61671.06","article-title":"Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting","volume":"68\u00a0","author":"Cohen","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004678.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/135245850000600603","article-title":"Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis","volume":"6","author":"Constantinescu","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1331\/1544345054003804","article-title":"Factors leading patients to discontinue multiple sclerosis therapies","volume":"45","author":"Daugherty","year":"2005","journal-title":"Journal of the American Pharmacists Association"},{"issue":"5","key":"10.1002\/14651858.CD004678.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/1531-8249(200005)47:5<686::AID-ANA29>3.0.CO;2-G","article-title":"Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial","volume":"47","author":"Seze","year":"2000","journal-title":"Annals of Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2007.08.036","article-title":"Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis","volume":"266","author":"De","year":"2008","journal-title":"Journal of the neurological sciences"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1352458508098269","article-title":"The results of two multicenter open label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymer mixture in patients with relapsing remitting multiple sclerosis","volume":"15","author":"Stefano","year":"2009","journal-title":"multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1468-1331.2007.01964.x","article-title":"A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate","volume":"14","author":"Debouverie","year":"2007","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp.2007.136440","article-title":"Predictors of the location of multiple sclerosis relapse","volume":"79","author":"Deen","year":"2008","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD004678.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1172\/JCI8970","article-title":"Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis","volume":"105","author":"Duda","year":"2000","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/brain\/124.4.705","article-title":"Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells","volume":"124","author":"Farina","year":"2001","journal-title":"Brain"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jns.2005.03.013","article-title":"Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?","volume":"233","author":"Rovaris","year":"2005","journal-title":"Journal of the neurological sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10549-005-1687-7","article-title":"On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"92","author":"Feigin","year":"2005","journal-title":"Breast cancer research and treatment"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1590\/S0004-282X2005000500002","article-title":"Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six month","volume":"63","author":"Fiore","year":"2005","journal-title":"Arquivos de Neuro-psiquiatria"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002826-200201000-00002","article-title":"Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration","volume":"25","author":"Flechter","year":"2002","journal-title":"Clinical Neuropharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(02)00047-3","article-title":"Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up","volume":"197","author":"Flechter","year":"2002","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/135248506ms1318oa","article-title":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patient","volume":"12","author":"Ford","year":"2006","journal-title":"Multiple Sclerosis"},{"issue":"11","key":"10.1002\/14651858.CD004678.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.57.11.1976","article-title":"HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis","volume":"57","author":"Fusco","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1352458508096687","article-title":"Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis","volume":"15","author":"Gajofatto","year":"2009","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1468-1331.2008.02504.x","article-title":"Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment","volume":"16","author":"Garcia-Barragan","year":"2009","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1191\/1352458505ms1206oa","article-title":"Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study","volume":"11","author":"Ghezzi","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1007\/s10072-005-0512-8","article-title":"Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study","volume":"26","author":"Ghezzi","year":"2005","journal-title":"Neurological sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1468-1331.2005.00936.x","article-title":"Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)","volume":"12","author":"Haas","year":"2005","journal-title":"European journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1610-0387.2007.06391.x","article-title":"Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate","volume":"5","author":"Harde","year":"2007","journal-title":"Journal der Deutschen.Dermatologischen.Gesellschaft"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.","volume":"6","author":"Johnson","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1191\/1352458503ms961oa","article-title":"Glatiramer acetate (Copaxone) : comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial","volume":"9","author":"Johnson","year":"2003","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0404.2004.00351.x","article-title":"Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data","volume":"111","author":"Johnson","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01376517-200808000-00007","article-title":"Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate","volume":"40","author":"Jolly","year":"2008","journal-title":"The Journal of neuroscience nursing"},{"issue":"5","key":"10.1002\/14651858.CD004678.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1172\/JCI200214380","article-title":"Glatiramer acetate (Copaxone) therapy induces CD8+ T cella response in patients with multiple sclerosis","volume":"109","author":"Karandikar","year":"2002","journal-title":"Journal of Clinical Investigation"},{"issue":"6","key":"10.1002\/14651858.CD004678.pub2-BIB0079|cit79","first-page":"349","article-title":"A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy","volume":"7","author":"Khan","year":"2001","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1191\/1352458505ms1234oa","article-title":"Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"11","author":"Khan","year":"2005","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1552-6569.2007.00206.x","article-title":"Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis","volume":"18","author":"Khan","year":"2008","journal-title":"Journal of neuroimaging"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0082|cit82","unstructured":"Kott E Kessler A Biran S Optic Neuritis in Multiple Sclerosis Patients Treated with Copaxone Journal of Neurology 1997 S23 4"},{"issue":"1352-4585","key":"10.1002\/14651858.CD004678.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1191\/1352458506ms1298oa","article-title":"Interferon treatment may trigger primary headaches in multiple sclerosis patients","volume":"12","author":"Mantia","year":"2006","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0084|cit84","first-page":"143","article-title":"Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis","volume":"27","author":"Lage","year":"2006","journal-title":"Work (Reading., Mass.)"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp.2007.124958","article-title":"Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients","volume":"79","author":"Page","year":"2008","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archneur.65.10.1378","article-title":"Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma","volume":"65","author":"Madray","year":"2008","journal-title":"Archives of neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.50.4.1127","article-title":"Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis","volume":"50","author":"Mancardi","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0088|cit88","first-page":"213","article-title":"Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial","volume-title":"Frontiers in Multiple Sclerosis: Clinical Research and Therapy","author":"Meiner","year":"1997"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00415-008-0924-5","article-title":"Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study","volume":"255","author":"Mesaros","year":"2008","journal-title":"Journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1007\/s10072-005-0509-3","article-title":"A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results","volume":"26 Suppl 4","author":"Milanese","year":"2005","journal-title":"Neurological sciences"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-5728(98)00191-X","article-title":"Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2\/Th3 immune-deviation","volume":"92","author":"Miller","year":"1998","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01376517-200602000-00008","article-title":"Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study","volume":"38","author":"Miller","year":"2006","journal-title":"The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1352458507085029","article-title":"Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"14","author":"Miller","year":"2008","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00415-006-0441-3","article-title":"Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis","volume":"254","author":"Neumann","year":"2007","journal-title":"Journal of neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1191\/1352458505ms1130cr","article-title":"Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate","volume":"11","author":"Nolden","year":"2005","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01376517-200810000-00006","article-title":"Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis","volume":"40","author":"Ollendorf","year":"2008","journal-title":"The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses"},{"issue":"5","key":"10.1002\/14651858.CD004678.pub2-BIB0098|cit98","first-page":"23","article-title":"[3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone]","volume":"105","author":"Orlova","year":"2005","journal-title":"Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova \/ Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov."},{"key":"10.1002\/14651858.CD004678.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1352458507082942","article-title":"Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis","volume":"14","author":"Patten","year":"2008","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1212\/01.wnl.0000194317.75449.91","article-title":"The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS","volume":"66","author":"P\u00f6llmann","year":"2006","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004678.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-5728(00)00263-0","article-title":"Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients","volume":"108","author":"Qin","year":"2000","journal-title":"Journal of Neuroimmunology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s00415-006-0178-z","article-title":"Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis","volume":"253","author":"Ramtahal","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1212\/01.WNL.0000158675.01711.58","article-title":"Severe anaphylactic reaction to glatiramer acetate with specific IgE","volume":"64","author":"Rauschka","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1191\/1352458505ms1173oa","article-title":"Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis","volume":"11","author":"Rio","year":"2005","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jns.2005.03.013","article-title":"Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?","volume":"233","author":"Rovaris","year":"2005","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1352458506070704","article-title":"Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European\/Canadian double-blind, placebo-controlled, MRI-monitored trial","volume":"13","author":"Rovaris","year":"2007","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2007.01.070","article-title":"Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial","volume":"255","author":"Schwid","year":"2007","journal-title":"Journal of the neurological sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11055-008-9102-6","article-title":"State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment","volume":"39","author":"Shipova","year":"2009","journal-title":"Neuroscience and behavioral physiology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.clineuro.2007.05.022","article-title":"Multiple sclerosis and Capgras' syndrome","volume":"109","author":"Sidoti","year":"2007","journal-title":"Clinical neurology and neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0110|cit110","first-page":"81","article-title":"Long-term follow up of glatiramer acetate compassionate use in Belgium","volume":"105","author":"Sindic","year":"2005","journal-title":"Acta Neurologica Belgica"},{"issue":"6","key":"10.1002\/14651858.CD004678.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaad.2006.04.069","article-title":"Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study","volume":"55","author":"Soares Almeida","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1212\/WNL.58.3.417","article-title":"MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients","volume":"58","author":"Sormani","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1191\/1352458505ms1178oa","article-title":"The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis","volume":"11","author":"Sormani","year":"2005","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1212\/01.wnl.0000276940.90309.15","article-title":"A composite score to predict short-term disease activity in patients with relapsing-remitting MS","volume":"69","author":"Sormani","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000094683","article-title":"Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis","volume":"116","author":"Then Bergh","year":"2006","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458507076385","article-title":"Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis","volume":"13","author":"Thouvenot","year":"2007","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/S0004-282X2006000100011","article-title":"Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients","volume":"64","author":"Tilbery","year":"2006","journal-title":"Arquivos de Neuro-psiquiatria"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0404.2007.00846.x","article-title":"Immunomodulatory treatment of multiple sclerosis in Norway","volume":"115","author":"Torkildsen","year":"2007","journal-title":"Acta Neurologica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0404.2007.00846.x","article-title":"Immunomodulatory treatment of multiple sclerosis in Norway","volume":"187","author":"Torkildsen","year":"2007","journal-title":"Acta Neurologica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1185\/030079907X188125","article-title":"Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population","volume":"23","author":"Twork","year":"2007","journal-title":"Current medical research and opinion"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1352458506074510","article-title":"Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis","volume":"13","author":"Valenzuela","year":"2007","journal-title":"Multiple sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0404.2005.00464.x","article-title":"The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients","volume":"112","author":"Vallittu","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1352458507085759","article-title":"Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis","volume":"14","author":"Vollmer","year":"2008","journal-title":"Multiple sclerosis"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1468-1331.2005.01084.x","article-title":"Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis","volume":"12","author":"Weder","year":"2005","journal-title":"European journal of neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archneur.56.3.319","article-title":"Neuropsychologic status in multiple sclerosis after treatment with glatiramer","volume":"56","author":"Weinstein","year":"1999","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/135245850100700107","article-title":"MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center","volume":"7","author":"Wolinsky","year":"2001","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S1748232107000110","article-title":"Optimal dosing of immunomodulating drugs: A dose-comparison study of GA in RRMS","volume":"3","author":"Wynn","year":"2008","journal-title":"Progress in Neurotherapeutics and Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0404.2007.00801.x","article-title":"Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis","volume":"116","author":"Ytterberg","year":"2007","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0129|cit129","first-page":"29","article-title":"Experience in copaxon treatment in Russia","volume":"105","author":"Zavalishin","year":"2005","journal-title":"Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova \/ Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov."},{"key":"10.1002\/14651858.CD004678.pub2-BIB0130|cit130","first-page":"111","article-title":"[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis]","volume":"Spec No 3","author":"Zavalishin","year":"2006","journal-title":"Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova \/ Ministerstvo.zdravookhraneniia.i meditsinskoi.promyshlennosti.Rossiiskoi.Federatsii., Vserossiiskoe.obshchestvo.nevrologov.[i] Vserossiiskoe.obshchestvo.psikhiatrov."},{"key":"10.1002\/14651858.CD004678.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-6-67","article-title":"Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis","volume":"6","author":"Ziemssen","year":"2008","journal-title":"Health and quality of life outcomes"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0404.2006.00627.x","article-title":"Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients","volume":"113","author":"Zwibel","year":"2006","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0134|cit133","first-page":"9","article-title":"PreCISe study Group. early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis (CDMS) in subjects presenting with a clinically isolated syndrome","volume":"70 Suppl","author":"Comi","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0133|cit134","unstructured":"Comi G Carr\u00e0 A Fazekas F Rieckmann P Bajenaru O Hillert J Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: subgroup analysis Multiple Sclerosis\/ World Congress on treatment and Research in Multiple Sclerosis Montreal 2008 2008 S38"},{"issue":"S1","key":"10.1002\/14651858.CD004678.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0022-510X(09)70004-8","article-title":"New options for early treatment of multiple sclerosis","volume":"277","author":"Tintore","year":"2009","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1191\/1352458503ms932oa","article-title":"Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials","volume":"9","author":"Martinelli Boneschi","year":"2003","journal-title":"Multiple Sclerosis"},{"issue":"6563","key":"10.1002\/14651858.CD004678.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/379343a0","article-title":"Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein","volume":"379","author":"Brocke","year":"1996","journal-title":"Nature"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1474-4422(05)00974-9","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis","volume":"4","author":"Caramanos","year":"2005","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)00975-0","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis","volume":"4","author":"Comi","year":"2005","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1002\/14651858.CD004678.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archderm.135.10.1277","article-title":"Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis (letter)","volume":"135","author":"Drago","year":"1999","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1212\/01.wnl.0000313034.46883.16","article-title":"Disability as an outcome in MS clinical trials","volume":"71","author":"Ebers","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0317167100002845","article-title":"Lipoatrophy in patients with multiple sclerosis on glatiramer acetate","volume":"31","author":"Edgar","year":"2004","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1212\/WNL.54.4.813","article-title":"Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment","volume":"54","author":"Ge","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0144|cit144","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for systematic Reviews of Interventions. Version 5.0.0(updated February 2008).The Cochrane Collaboration, 2008 www.cochrane-handbook. org","DOI":"10.1002\/9780470712184"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0145|cit145","first-page":"287","article-title":"Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis","volume":"68","author":"Hwang","year":"2001","journal-title":"Cutis"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of randomised trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"issue":"11","key":"10.1002\/14651858.CD004678.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0148|cit148","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s004150050568","article-title":"Localized lipoatrophy after prolonged treatment with copolymer 1","volume":"247","author":"Mancardi","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0150|cit150","first-page":"26","article-title":"Aletuzumab versus interferon beta-1a;implications for pathology and trial design","volume":"8","author":"McFarland","year":"2008","journal-title":"neurology"},{"issue":"11","key":"10.1002\/14651858.CD004678.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1474-4422(04)00899-3","article-title":"Lack of evidence for use of glatiramer acetate in multiple sclerosis","volume":"3","author":"Munari","year":"2004","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1474-4422(05)00976-2","article-title":"Evidence for use of glatiramer acetate in multiple sclerosis (Authors' reply)","volume":"4","author":"Munari","year":"2005","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004678.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004678.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0155|cit155","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.10290","article-title":"assessment of different treatment failure criteria in a Cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta:implications for clinical trials","volume":"52","author":"Rio","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1002\/14651858.CD004678.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ana.20740","article-title":"Defining the response to interferon beta in relapsing-remitting multiple sclerosis patients","volume":"59","author":"Rio","year":"2006","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/PL00000576","article-title":"Coplymer 1: from basic research to clinical application","volume":"53","author":"Teitelbaum","year":"1997","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"issue":"2","key":"10.1002\/14651858.CD004678.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ana.410010207","article-title":"Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis","volume":"1","author":"Wisniewski","year":"1977","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004678.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta-blockade during and after myocardial infarction: an overview of the randomised trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004678.pub2-BIB0161|cit161","article-title":"Therapy with glatiramer acetate for multiple sclerosis","author":"Munari","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004678.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:17:42Z","timestamp":1776115062000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004678.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,5,12]]},"references-count":161,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004678.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,12]]}}}